Biomy, Inc.
June 17, 2025
Company Presentation
AI and Digital Health
153B
Biomy, Inc. is a Japanese company that developed DeepPathFinder™, a unique AI/DL-automated digital pathology algorithm that can detect, identify, and quantify immune cells in tumor and tumor micro-environment tissues from H&E only (demo movie: https://vimeo.com/1086813571/ec43dbcac9).
Furthermore, DeepPathFinder™ is equipped with Spatial Biology features that deliver tremendous value for Precision Medicine (eg, diagnosis, patient stratification, evaluation of treatment response, prognosis) as well as for the discovery of novel Pathological Biomarkers in multiple therapeutic areas such as Immuno-Oncology, and Auto-Immune and Inflammatory Diseases.
Company HQ City:
Tokyo
Company HQ State:
Tokyo Prefecture
Company HQ Country:
Japan
Year Founded:
2019
Lead Product in Development:
DeepPathFinder™
CEO
Teppei KONISHI, ME
CEO & Co-Founder
Development Phase of Lead Product
Multiple Products in Market
When you expect your next catalyst update?
Expansion into US and EU markets.
What is your next catalyst (value inflection) update?
6 months.
Website
www.biomy-tech.com
Primary Speaker
)
)
)
)
){kind=logo}
){kind=logo}
)
){kind=logo}
)
){kind=logo}
){kind=logo}